Managing joint pain in osteoarthritis: Safety and efficacy of hylan G-F 20

Journal of Pain Research

Volumn 2, Issue , 2009, Pages 87-98

  Conduah, Augustine H ^a   Baker III, Champ L ^a   Baker Jr , Champ L ^a  

^a Hughston Sports Medicine Foundation   (United States)

Author keywords

Hyaluronic acid; Hylan G F 20; Knee; Osteoarthritis; Viscosupplementation

Indexed keywords

ARTZAL; BETAMETHASONE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EUFLEXXA; HYALURONIC ACID; HYLAN G F 20; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TRIAMCINOLONE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTHROCENTESIS; CARDIOVASCULAR DISEASE; CHONDROPROTECTION; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EFFUSION; GASTROINTESTINAL SYMPTOM; HIP OSTEOARTHRITIS; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE WARMTH; JOINT CAVITY; JOINT SWELLING; KIDNEY DISEASE; KNEE OSTEOARTHRITIS; KNEE PAIN; MOLECULAR WEIGHT; MULTIPLE CYCLE TREATMENT; NONHUMAN; OSTEOARTHRITIS; PATIENT COMPLIANCE; POSTOPERATIVE PAIN; PSEUDOGOUT; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; SINGLE DRUG DOSE; SYNOVITIS; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISCOELASTICITY;

EID: 77953448057     PISSN: None     EISSN: 11787090     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 1998;41(8):1343-1355.
2. Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006;54(1):226-229.
3. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290(18):2443-2454.
4. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137-162.
5. American College of Rheumatology Subcommittee on Arthritis Guidelines. Recommendations for the Medical Management of Osteoarthritis of the Hip and Knee. Arthritis Rheum. 2000;43(9):1905-1915.
6. Wang CT, Lin J, Chang CJ, Lin YT, Hou SM. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg Am. 2004;86(3):538-545.
7. Tytherleigh-Strong G, Hurtig M, Miniaci A. Intra-articular hyaluron following autogenous osteochondral grafting of the knee. Arthroscopy. 2005;21(8):999-1005.
8. Hempfling H. Intra-articular hyaluronic acid after knee arthroscopy: a two-year study. Knee Surg Sports Traumatol Arthrosc. 2007;15(5): 537-546.
9. Kawasaki K, Ochi M, Uchio Y, Adachi N, Matsusaki M. Hyaluronic acid enhances proliferation and chondroitin sulfate synthesis in cultured chondrocytes embedded in collagen gels. J Cell Physiol. 1999;179 (2):142-148.
10. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheum. 1993;39(Aug):3-9.
11. Gibbs DA, Merrill EW, Smith KA, Balazs EA. Rheology of hyaluronic acid. Biopolymers. 1968;6(6):777-791.
12. Brockmeier SF, Shaffer BS. Viscosupplementation therapy for osteoarthritis. Sports Med Arthrosc Rev. 2006;14(3):155-162.
13. Watterson JR, Esdaile JM. Viscosupplementation: therapeutic mechanisms and clinical potential in osteoarthritis of the knee. J Am Acad Orthop Surg. 2000;8(5):277-284.
14. Greenwald RA. Oxygen radicals, inflammation, and arthritis: pathophysiological considerations and implications for treatment. Semin Arthritis Rheum. 1991;20(4):219-240.
15. Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther. 2003;5(2):54-67.
16. Balazs EA. The physical properties of synovial fluid and the specific role of hyaluronic acid. In: Helfet AJ, editor. Disorders of the Knee. Philadelphia: JB Lippincott; 1982. p. 61-74.
17. Fraser JR, Kimpton WG, Pierscionek BK, Cahill RN. The kinetics of hyaluronan in normal and acutely inflamed synovial joints: observations with experimental arthritis in sheep. Semin Arthritis Rheum. 1993; 22(6 suppl 1):9-17.
18. Yagishita K, Sekiya I, Sakaguchi Y, Shinomiya K, Muneta T. The effect of hyaluronan on tendon healing in rabbits. Arthroscopy. 2005;21(11):1330-1336.
19. Forrester JV, Balazs EA. Inhibition of phagocytosis by high molecular weight hyaluronate. Immunology. 1980;40(3):435-446.
20. Håkansson L, Hällgren R, Venge P. Regulation of granulocyte function by hyaluronic acid: In vitro and in vivo effects on phagocytosis, locomotion, and metabolism. J Clin Invest. 1980;66(2):298-305.
21. Tamoto K, Tada M, Shimada S, Nochi H, Mori Y. Effects of high-molecular-weight hyaluronates on the functions of guinea pig polymorphonuclear leukocytes. Semin Arthritis Rheum. 1993; 22(6 Suppl 1):4-8.
22. 2 and cAMP of synovial fluid. Clin Exp Rheumatol. 1989;7(3):247-250.
23. Miyakoshi N, Kobayashi M, Nozaka K, Okada K, Shimada Y, Itoi E. Effects of intraarticular administration of basic fibroblast growth factor with hyaluronic acid on osteochondral defects of the knee in rabbits. Arch Orthop Trauma Surg. 2005;125(10):683-692.
24. 14C] arachidonic acid release from labeled human synovial fibroblasts. Jpn J Pharmacol. 1992;60(2):79-84.
25. Ghosh P. The role of hyaluronic acid (hyaluronan) in health and disease: interactions with cells, cartilage and components of synovial fluid. Clin Exper Rheumatol. 1994;12(1):75-82.
26. Gomis A, Pawlak M, Balazs EA, Schmidt RF, Belmonte C. Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthritis Rheum. 2004;50(1): 314-326.
27. Pozo MA, Balazs EA, Belmonte C. Reduction of sensory responses to passive movements of inflamed knee joints by hylan. A hyaluronan derivative. Exp Brain Res. 1997;116(1):3-9.
28. Moreland LW. Intraarticular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther. 2003;5(2):54-67.
29. Adams ME, Brandt KD. Hypertrophic repair of canine articular cartilage in osteoarthritis after anterior cruciate ligament transection. J Rheumatol. 1991;18(3):428-435.
30. Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Médicis R. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol. 1996;23(9):1579-1585.
31. Kotevoglu N, Iyibozkurt PC, Hiz O, Toktas H, Kuran B. A prospective randomized controlled clinical trail comparing the efficacy of different molecular weight hyaluronan solutions in the treatment of knee osteoarthritis. Rheumatol Int. 2006;26(4):325-330.
32. Wobig M, Bach G, Beks P, et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther. 1999;21(9):1549-1562.
33. Peyron JG, Balazs EA. Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joints. Pathol Biol (Paris). 1974;22(8):731-736.
34. Dixon AS, Jacoby RK, Berry H, Hamilton EB. Clinical trial of intraarticular injection of sodium hyaluronate in patients with osteoarthritis of the knee. Curr Med Res Opin. 1988;11(4):205-213.
35. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;(2):CD005321.
36. Conrozier T, Jerosch J, Beks P, et al. Prospective, multi-centre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study. Arch Orthop Trauma Surg. 2009;129(3):417-423.
37. Adams ME, Atkinson MH, Lussier AJ, et al. The role of viscosupplementation with hylan G-F 20 in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDS) and NSAIDS alone. Osteoarthritis Cartilage. 1995;3(4):213-225.
38. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998;20(3):410-423.
39. Raynauld JP, Torrance G, Band P, et al. A prospective, randomized, pragmatic, health outcomes trial evaluation the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2: clinical results. Osteoarthritis Cartilage. 2002;10(7): 506-517.
40. Karlsson J, Sjögren S, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis: a controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford). 2002;41(11):1240-1248.
41. Waddell DD, Bricker DC. Clinical experience with the effectiveness and tolerability of hylan G-F 20 in 1047 patients with osteoarthritis of the knee. J Knee Surg. 2006;19(1):19-27.
42. Modawal A, Ferrer M, Choi HK, Castle HK. Hyaluronic acid injections relieve knee pain. J Fam Pract. 2005;54(9):758-767.
43. Divine JG, Zazulak BT, Hewett TE. Viscosupplementation for knee osteoarthritis: a systematic review. Clin Orthop Relat Res. 2007;455(Feb):113-122.
44. Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res Clin Exper. 1994;55:220-232.
45. Dickson DJ, Hosie G, English JR. A double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. J Clin Res. 2001;4:41-52.
46. Brzusek D, Petron D. Treating knee osteoarthritis with intra-articular hyaluronans. Curr Med Res Opin. 2008;24(12):3307-3322.
47. Huskin JP, Vandekerckhove B, Delincé, et al. Multicentre, prospective, open study to evaluate the safety and efficacy of hylan G-F 20 in knee osteoarthritis subjects presenting with pain following arthroscopic meniscectomy. Knee Surg Sports Traumatol Arthrosc. 2008;16(8): 747-752.
48. Reichenbach S, Blank S, Rutjes AWS, et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum. 2007;57(8):1410-1418.
49. Evanich JD, Evanich CJ, Wright MB, Rydlewicz JA. Clin Orthop Relat Res. 2001;390(Feb):173-181.
50. Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and shortterm effectiveness of hylan G-F 20 in 453 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21(8): 1261-1269.
51. Raman R, Dutta A, Day N, Sharma HK, Shaw CJ, Jonson GV. Efficacy of hylan G-F 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee - a prospective randomized trial. Knee. 2008;15(4):318-324.
52. Waddell DD. Viscosupplementation with hyaluronans for osteoarthritis of the knee. Drugs Aging. 2007;24(8):629-642.
53. Caborn D, Rush J, Lanzer W, Parenti D, Murray C; Sunvisc 901 Study Group. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J Rheumatol. 2004;31(2): 333-343.
54. Leopold SS, Redd BB, Warme WJ, Wehrle PA, Pettis PD, Shott S. Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee: a prospective, randomised trial. J Bone Joint Surg Am. 2003;85(7):1197-1203.
55. Jüni P, Reichenbach S, Trelle S, et al. Efficacy and safety if intra-articular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum. 2007;56(11): 3610-3619.
56. Goldberg VM, Buckwalter JA. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthritis Cartilage. 2005;13(3):215-224.
57. Waddell DD, Cefalu CA, Bricker DC. A second course of hylan G-F 20 for the treatment of osteoarthritic knee pain: 12-month patient follow-up. J Knee Surg. 2005;18(1)7-15.
58. Raynauld JP, Goldsmith CH, Bellamy N, et al. Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis. Osteoarthritis Cartilage. 2005;13(2):111-119.
59. Pagnano M, Westrich G. Successful nonoperative treatment of chronic osteoarthritis pain of the knee: safety and efficacy of re-treatment with intra-articular hyaluronans. Osteoarthritis Cartilage. 2005;13(9): 751-761.
60. Leopold SS, Warme WJ, Pettis PD, Shott S. Increased frequency of acute local reaction to intra-articular hylan G-F 20 in patients receiving more than one course of treatment. J Bone Joint Surg Am. 2002;84(9):1619-1623.
61. Hammesfahr JFR, Knopf AB, Stitik T. Safety of intra-articular hyaluronates for pain associated with osteoarthritis of the knee. Am J Orthop. 2003;32(6):277-283.
62. Waddell DD. The tolerability of viscosupplementation: low incidence and clinical management of local adverse events. Curr Med Res Opin. 2003;19(7):575-580.
63. Puttick MPE, Wade JP, Chalmers A, Connell DG, Rangno KK. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol. 1995;22(7):1311-1314.
64. Goldberg VM, Coutts RD. Pseudoseptic reactions to hylan viscosupplementaion: diagnosis and treatment. Clin Orthop Relat Res. 2004;419(Feb):130-137.
65. Strauss EJ, Hart JA, Miller MD, Altman RD, Rosen JE. Hyaluronic acid viscosupplementation and osteoarthritis: current uses and future directions. Am J Sports Med. 2009. [Feb 3 Epub ahead of print].
66. Altman RD. Intra-articular sodium hyaluronate in osteoarthritis of the knee. Semin Arthritis Rheum. 2000;30(2 Suppl 1):11-18.
67. Frizziero L, Pasquali-Ronchetti I. Intra-articular treatment of osteoarthritis of the knee: an arthroscopic and clinical comparison between sodium hyaluronate (500-700 kDa) and methylprednisolone acetate. J Orthopaed Traumatol. 2002;3:89-96.
68. Gray RG, Gottlieb NL. Intra-articular corticosteroids. An updated assessment. Clin Orthop Relat Res. 1983;177(Jul-Aug):235-263.
69. Jackson DW, Evans NA, Thomas BM. Accuracy of needle placement into the intra-articular space of the knee. J Bone Joint Surg Am. 2002;84(9):1522-1527.
70. Ali Y, Weinstein M, Jokl P. Acute pseudogout following intra-articular injection of high molecular weight hyaluronic acid. Am J Med. 1999;107(6):641-642.
71. Kroesen S, Schmid W, Theller R. Induction of an acute attack of calcium pyrophosphate dihydrate arthritis by intra-articular injection of hylan G-F 20 (Synvisc). Clin Rheumatol. 2000;19(2):147-149.
72. Hamburger MI, Lakhanpal S, Mooar PA, Oster D. Intra-articular hyaluronans: a review of product-specific safety profiles. Semin Arthritis Rheum. 2003;32(5):296-309.
73. Marino AA, Waddell DD, Kolomytkin OV, Pruett S, Sadasivan KK, Albright JA. Assessment of immunologic mechanisms for flare reactions to Synvisc® . Clin Orthop Relat Res. 2006;442(Jan): 187-194.
74. Allen E, Krohn K. Adverse reaction to hylan GF-20. J Rheumatol. 2000;27(6):1572.
75. Martens PB. Bilateral symmetric inflammatory reaction to hylan G-F 20 injection. Arthritis Rheum. 2001;44(4):978-979.
76. Waddell DD, Cefalu CA, Bricker DC. An open-label study of a second course of hylan G-F 20 for the treatment of pain associated with knee osteoarthritis. Curr Med Res Opin. 2003;19(6):499-507.
77. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum. 2000;43(9): 1905-1915.
78. Arthritis Pain Guideline Panel. Guidelines for the management of pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis. Glenview: American Pain Society. 2002.
79. Kean WF, Rainsford KD, Kean IR. Management of chronic musculoskeletal in the elderly: opinions on oral medication use. Inflammopharmacology. 2008;16(2):53-75.
80. Antman EM, Bennett JS, Daugherty A, et al. Circulation. 2007; 115(12):1636-1642.
81. Kahan A, Lleu PL, Salin L. Prospective randomized study comparing the medico-economic benefits of hylan G-F 20 vs conventional treatment in knee osteoarthritis. Joint Bone Spine. 2003;70(4): 276-281.
82. Waddell DD, Bricker DC. Total knee replacement delayed with hylan G-F 20 use in patients with grade IV osteoarthritis. J Manag Care Pharm. 2007;13(3):113-121.
83. Bell M, Fallaha M, Lenczner E, et al. Viscosupplementation with hylan G-F 20 in total knee replacement candidates: an effective pain management therapy that may delay surgery. [Abstract] Osteoarthritis Cartilage. 1999;7(Suppl A):S30.
84. Chevalier X, Jerosch J, Goupille P, et al. Single, intra-articular treatment with 6 mL of hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multi-centre, double-blind, placebo-controlled trial. Ann Rheum Dis. 2009. [Mar 19 Epub ahead of print].
85. Baker CL, Ferguson CM. Future treatment of osteoarthritis. Orthopedics. 2005;28(2 Suppl):S227-S234.
86. Amiel D, Toyoguchi T, Kobayashi K, Bowden K, Amiel ME, Healey RM. Long-term effect of sodium hyaluronate (Hyalgan) on osteoarthritis progression in a rabbit model. Osteoarthritis Cartilage. 2003;11(9):636-643.
87. Hulmes DJ, Marsden ME, Strachan RK, Harvey RE, McInnes N, Gardner DL. Intra-articular hyaluronate in experimental rabbit osteoarthritis can prevent changes in cartilage proteoglycan content. Osteoarthritis Cartilage. 2004;12(3):232-238.
88. Smith MM, Cake MA, Ghosh P, Schiavinato A, Read RA, Little CB. Significant synovial pathology in a meniscectomy model of osteoarthritis: modification by intraarticular hyaluronan therapy. Rheumatology (Oxford). 2008;47(8):1172-1178.
89. Jubb RW, Piva S, Beinat L, Dacre J, Gishen P. A randomised, placebo (saline)-controlled clinical trial of the structure modifying effect of 500-730 Kda sodium hyaluronate (Hyalgan) in osteoarthritis of the knee. Int J Clin Pract. 2003;57(6):467-474.
90. Bagga H, Burkhardt D, Sambrook P, March L. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol. 2006;33(5):946-950.
91. Zietz PM, Selesnick H. The use of hylan G-F 20 after knee arthroscopy in an active patient population with knee osteoarthritis. Arthroscopy. 2008;24(4):416-422.
92. Vad VB, Sakalkale D, Sculco TP, Wickiewicz TL. Role of hylan G-F 20 in treatment of osteoarthritis of the hip joint. Arch Phys Med Rehabil. 2003;84(8):1224-1226.
93. Tikiz C, Unlü Z, Sener A, Efe M, Tüzün C. Comparison of efficacy of lower and higher molecular weight viscosupplementation in the treatment of hip osteoarthritis. Clin Rheumatol. 2005;24(3):244-250.
94. Migliore A, Tormenta S, Massafra U, et al. Intra-articular administration of hylan G-F 20 in patients with symptomatic hip osteoarthritis: tolerability and effectiveness in a large cohort study in clinical practice. Curr Med Res Opin. 2008;24(5):1309-1316.
95. Conrozier T, Bertin P, Bailleul F, et al. Clinical response to intra-articular injections of hylan G-F 20 in symptomatic hip osteoarthritis: the OMERACT-OARSI criteria applied to the results of a pilot study. Joint Bone Spine. 2006;73(6):705-709.
96. Altman RD, Moskowitz R, Jacobs S, et al. Double-blind, randomized trial of intra-articular injection of sodium hyaluronate (Hyalygan) for the treatment of chronic shoulder pain. Arthritis Rheum. 2005;52(Suppl):S461.
97. Schumacher HR, Meador R, Sieck M, Mohammed Y. Pilot investigation of hyaluronate injections for first metacarpalcarpal (MC-C) osteoarthritis. J Clin Rheumatol. 2004;10(2): 59-62.
98. Marshall KW. Intra-articular hyaluronan therapy. Foot Ankle Clin N Am. 2003;8(2):221-232.
99. Witteveen AG, Giannini S, Guido G, et al. A prospective multi-centre, open study of the safety and efficacy of hylan G-F 20 (Synvisc) in patients with symptomatic ankle (talo-crural) osteoarthritis. Foot Ankle Surg. 2008;14(3):145-152.
100. Luciani D, Cadossi M, Tesei F, Chiarello E, Gianni S. Viscosupplementation for grade II osteoarthritis of the ankle: a prospective study at 18 months' follow up. Chir Organi Mov. 2008;92(3): 155-160.
101. Silverstein E, Leger R, Shea KP. The use of intra-articular hylan G-F 20 in the treatment of symptomatic osteoarthritis of the shoulder: a preliminary study. Am J Sports Med. 2007;35(6): 979-985.
102. Heyworth BE, Lee JH, Kim PD, Lipton CB, Strauch RJ, Rosenwasser MP. Hylan versus corticosteroid versus placebo for treatment of basal joint arthritis: a prospective, randomized, double-blinded clinical trial. J Hand Surg Am. 2008;33(1):40-48.